ADC Biotechnology secures $11m for commercial biomanufacturing plant

By Gareth Macdonald

- Last updated on GMT

ADC Biotechnology has announced it will spend $11m ($9.2m) build a bio-conjugation facility at a site in Deeside, North Wales.

The facility – which is due to be operational in 2018 – will produce antibody-drug conjugates (ADC) for clinical trials and small scale commercial batches. It will also house R&D technical services and quality control laboratories, warehousing and capacity for process development.

Funding for the plant will be provided by Maven VCTs, Seneca and Finance Wales. The Welsh Assembly Government is also providing ADC with a grant.

The investment marks the Wales-based contractor’s move into clinical and commercial production. Previously, its manufacturing focus has been on the production of ADCs for R&D and preclinical development.

ADC’s core technology is its “lock-release” platform.

It works by covalently ‘locking’ an antibody to solid polymer beads, prior to conjugation, releasing them as a clean drug substance.

ADC claims its technology is used by 20 customers, including several major pharmaceutical firms.

CEO Charlie Johnson said: “We already have confirmation that many of our existing customers will use the facility for clinical development.

We anticipate adding a number of the new targets entering clinical development from customers in the USA and Europe - especially in light of the added value we can provide through Lock-Release​” he added.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more